Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.
Revenue of Burning Rock Biotech Limited (BNR)
Revenue in 2023 (TTM): $537.44 M
According to Burning Rock Biotech Limited's latest financial reports the company's current revenue (TTM) is $537.44 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Burning Rock Biotech Limited
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $537.44 M | $363.23 M | $-537,869,000 | $-651,301,000 | $-653,689,000 |
| 2022 | $563.24 M | $380.04 M | $-856,311,000 | $-969,248,000 | $-971,233,000 |
| 2021 | $507.86 M | $364.15 M | $-746,496,000 | $-795,798,000 | $-796,697,000 |
| 2020 | $429.9 M | $313.92 M | $-373,259,000 | $-407,235,000 | $-373,706,000 |
| 2019 | $381.68 M | $273.33 M | $-136,380,000 | $-169,156,000 | $-168,337,000 |
| 2018 | $208.87 M | $135.06 M | $-135,866,000 | $-177,497,000 | $-177,497,000 |
| 2017 | $111.17 M | $71.7 M | $-99,554,000 | $-131,275,000 | $-131,275,000 |